Index Performance
Overview
Description
The radiopharmaceutical space is garnering significant attention as advancements in medical technologies continue to enhance the precision and effectiveness of cancer diagnostics and treatment. The industry's growth outlook is robust, supported by expanding applications in both diagnostic imaging and targeted cancer therapies. Radioligand treatment is distinguished by its ability to deliver targeted radiation directly to cancer cells, often resulting in fewer side effects compared to other therapies. Meanwhile, the outlook for isotope-based imaging remains positive as it continues to be an essential tool in early and accurate disease diagnosis, which is vital for timely and effective patient management. This index was generated with help from Thematic Analyst.
- Inception Date12/03/2024
- WeightingEqual
- # of holdings17
What's inside?
Holdings
All holdings as of December 4, 2025
| Immunome, Inc. (IMNM) | 10.92% | $1.84B | -100.00% | N/A | 78.66 |
| Plus Therapeutics, Inc. (PSTV) | 8.05% | $90.02M | -4.05% | 93.84% | 10.82 |
| Crinetics Pharmaceuticals, Inc. (CRNX) | 7.14% | $4.50B | N/A | -607.69% | 1,876.49 |
| Eli Lilly & Co. (LLY) | 6.89% | $959.08B | 53.87% | 82.91% | 12.09 |
| Lantheus Holdings, Inc. (LNTH) | 6.27% | $4.10B | 1.39% | 57.91% | 2.43 |
| Bristol Myers Squibb Co. (BMY) | 5.97% | $105.76B | 2.77% | 66.00% | 2.63 |
| GE Healthcare Technologies, Inc. (GEHC) | 5.63% | $37.59B | 5.76% | 38.73% | 2.04 |
| Novartis AG (NOVN) | 5.55% | $254.17B | 0.19% | 74.58% | 4.60 |
| RadNet, Inc. (RDNT) | 5.42% | $6.26B | 13.39% | 6.66% | 3.65 |
| Mirion Technologies, Inc. (MIR) | 5.33% | $6.47B | 7.88% | 37.34% | 6.97 |
| Bicycle Therapeutics Plc (BCYC) | 5.26% | $494.85M | 331.43% | 85.03% | -3.72 |
| BWX Technologies, Inc. (BWXT) | 5.22% | $16.30B | 28.91% | 21.87% | 6.00 |
| Telix Pharmaceuticals Ltd. (TLX) | 5.12% | $3.26B | 55.85% | 65.16% | 10.68 |
| Actinium Pharmaceuticals, Inc. (ATNM) | 4.66% | $45.23M | N/A | -128.89% | -25.94 |
| Siemens Healthineers AG (SHL) | 4.59% | $55.56B | 4.53% | 38.63% | 2.77 |
| Eckert & Ziegler SE (EUZ) | 4.28% | $1.13B | 7.42% | 45.35% | 3.43 |
| Cellectar Biosciences, Inc. (CLRB) | 3.73% | $16.11M | N/A | N/A | N/A |